PERSONAL DETAIL


ASSOCIATE PROF. DR. MARNIZA BINTI SAAD

Faculty of Medicine Dean's Office
Faculty of Medicine
 
  +60379492185
  +60379563072
  marniza@um.edu.my
 Faculty of Medicine Dean's Office, Faculty of Medicine, University of Malaya, 50603 Kuala Lumpur, W.Persekutuan Kuala Lumpur, Malaysia
 
ResearcherID Link
  http://www.researcherid.com/rid/B-8947-2010


BIBLIOMETRIC DATA


 Total Articles in Publication List  4
 Articles With Citation Data  4
 Sum of the Times Cited   35
 Average Citations per Article   8.75
 h-index   3
 Co-authors   Collaboration Network
 This information is generated from http://researcherid.com

BIOGRAPHY


Marniza Saad is a Consultant Clinical Oncologist at the Department of Clinical Oncology, University Malaya Medical Centre (UMMC) Kuala Lumpur, Malaysia, since 2006. She also holds the Associate Professor post at the Faculty of Medicine, University Malaya (UM) Kuala Lumpur. She obtained her Medical Degree from University of Wales College of Medicine, Cardiff, United Kingdom in 1997. She completed her general medical training within the South Wales Medical Rotation in 2000. In 2001 she joined UM as a trainee lecturer in Oncology. She pursued her formal training as clinical oncologist at the Velindre Cancer Centre in Cardiff, UK from 2002 to 2006 and was awarded the Fellowship of Royal College of Radiologists (Clinical Oncology) in 2006. She is now the supervisor and internal examiner for the Master of Clinical Oncology programme in UM since May 2006. Working within the department Education Committee, she has deep passion for education and training of future oncologists in Malaysia. She was the Head of Department of Clinical Oncology UMMC from 2013 to 2015. During this time she was overseeing the development of Stereotactic Radiosurgery/Radiotherapy (SRS/SRT) and Intensity Modulated Radiotherapy (IMRT) with the designated expert teams, until successful initiation of the services in UMMC in May and September 2015, respectively. She is currently in the UMMC Intra-Operative Radiotherapy Working Group to introduce the service in UMMC in the near future. She is an Exco Committee member for Malaysia Oncological Society since 2013. She is a member of College of Radiology Academy of Medicine Malaysia and European Society for Medical Oncology. Her areas of special interest include genitourinary cancer, sarcoma, breast and gastrointestinal cancers. She is the principle investigator for several international clinical trials mainly in urological cancers and regularly speaks in the areas of her interest at both local and international conferences. 


ACADEMIC QUALIFICATION
(Qualification), (Institution).



PROFESSIONAL
(Organisation), (Role), (Year), (Level).


  • Royal College of Radiologists, Member, 2006, (International)
  • MALAYSIA ONCOLOGICAL SOCIETY, Life Membership, 2006, (National)
  • Academy of Medicine, Member, 2008, (National)
  • EUROPEAN SOCIETY FOR MEDICAL ONCOLOGY (ESMO), Member, 2011 to 2020, (International)
  • Sout East Asia Radiation Oncology Group, Committee Members, 2011 to 2014, (International)
  • Medical Protection Society, Member, 2011 to 2012, (International)
  • Nasopharyngeal Carcinoma Society of Malaysia, Member, 2012, (International)
  • National Specialist Register Malaysia, Member, 2012, (National)
  • European Society of Radiology, Member, 2013, (International)
  • Malaysia Oncological Society, Exco Commitee Member, 2013 to 2015, (National)
  • Malaysia Oncology Society, Exco Commitee Member, 2015 to 2017, (National)

ADMINISTRATIVE DUTIES
(Role), (Level), (Start date),(End Date).


  • Head, Clinical Oncology Unit, Faculty of Medicine, 01/08/2014 to 31/08/2015
  • Head, Clinical Oncology Unit, Faculty of Medicine, 01/09/2013 to 30/06/2014
  • Lead for Clinical Oncology National Curriculum Project, National, 03/06/2016 (Ongoing)
  • Member UMMC CIGMIT Technical Committee, University Malaya, 16/05/2016 (Ongoing)
  • Clinical Oncology Specialty Committee for Masters of Clinical Oncology, Clinical Oncology Unit, Faculty of Medicine, 01/09/2015 to 31/08/2017
  • Chairperson for Pharm UMMC Committee, Clinical Oncology Unit, Faculty of Medicine, 01/09/2015 to 29/02/2016
  • Education Committee Member Department of Clinical Oncology UMMC, Clinical Oncology Unit, Faculty of Medicine, 01/09/2015 to 31/08/2017
  • Chairperson for Hospital Infection Control Committee UMMC, Clinical Oncology Unit, Faculty of Medicine, 01/09/2015 to 29/02/2016
  • Clinical Oncology National Curriculum Writing Group., National, 01/04/2015 to 30/06/2017
  • Committee Member of Jawatankuasa Ijazah Tinggi Fakulti Perubatan, Faculty, 01/10/2014 to 01/06/2016
  • Committee Member for Radiation Protection Committee, Faculty, 01/04/2014 to 31/08/2015
  • Deputy Chairperson for Breast Cancer Patient Fund, University Malaya, 06/11/2013
  • eMR Clinical Champion, Faculty, 01/10/2013
  • Head Of Department, Faculty, 01/09/2013
  • Chairperson for Clinical Oncology Trust Fund, Faculty, 01/09/2013 to 31/08/2015
  • Research Coordinator for Master of Clinical Oncology, University Malaya, 01/06/2012 to 08/07/2013 (Coordinator for Research Component Masters of Clinical Oncology)
  • MAC Committee Member, University Malaya, 01/11/2011 to 31/08/2015 (None)
  • Deputy Chairperson for Clinical Oncology Trust Fund., Faculty, 01/08/2011
  • Member in Quality Improvement Team Project on Nutritional Assessment for Patients with Cancer. 2010., Faculty, 30/09/2010 to 04/01/2010
  • Department Quality Manager, Faculty, 27/08/2010
  • Clinical Oncology Specialty Committee for Masters of Clinical Oncology, National, 01/01/2009 (Clinical Oncology Specialty Committee)
  • Committee member for Curriculum Development for Nursing Programmes., Faculty, 15/11/2006 to 30/06/2006
  • Coordinator for Part 2 programme Masters of Clinical Oncology, Faculty, 20/05/2006

AREAS OF EXPERTISE
(Area).


  • Radiotherapy, Clinical Oncology, Chemotherapy, Hormonal Therapy, Targeted Therapy, Genitourinary Cancer, Soft Tissue Sarcoma, Bone Sarcoma, Gastrointestinal Cancer, Breast Cancer


RECENT SELECTED PUBLICATIONS
(Publication).


Chapter in Book

2014
  • Rajandram R, Ong TA, SAAD M. The challenges of drug resistance in renal cell carcinoma. In: Morais, C. ed. Advances in drug resistance research, Nova Science Publishers, N.Y., USA. 
Article in Academic Journals

2019
  • Saad M, Alip A, Lim J, Abdullah MM, Chong FLT, Chua CB, Ismail F, Khong RK, Lim CS, Loh CS, Malek R, Mohd Ghani KA, Md Noor I, Md Yusoff NA, Nasuha NA, Razack A, Soo Hoo HF, Sundram M, Tan HM, Thiagarajan M, Teh GC, Voon PJ, Ong TA. (2019). Management of advanced prostate cancer in a middle-income country: real-world consideration of the Advanced Prostate Cancer Consensus Conference (APCCC) 2017. BJUI Int. 124: 373-382 doi:10.1111/bju.14807. (ISI-Indexed)
  • Nirmala Bhoo-Pathy, Chiu-Wan Ng, Gerard Chin-Chye Lim, Nor Saleha Ibrahim Tamin, Richard Sullivan, Nanthini Thevi Bhoo-Pathy, Matin Mellor Abdullah, Merel Kimman, Shridevi Subramaniam, MARNIZA SAAD, Nur Aishah Taib, Kian-Meng Chang, Pik-Pin Goh, Cheng-Har Yip, Financial Toxicity After Cancer in a Setting With Universal Health Coverage: A Call for Urgent Action. Journal of Onccology Practice, Mar 2019. (ISI-Indexed)
  • Nurul Aqilah Mohd Nor, Nur Aishah TaibEmail author, MARNIZA SAAD, Hana Salwani Zaini, Zahir Ahmad, Yamin Ahmad and Sarinder Kaur Dhillon. (2019). Development of electronic medical records for clinical and research purposes: the breast cancer module using an implementation framework in a middle income country- Malaysia. BMC Bioinformatics201919 (Suppl 13) :402 (ISI-Indexed)

2018
  • Yap, N.Y., Khoo, W.T., Perumal, K., Ng, K.A., Rajandram,R., Alip, A., SAAD, M. and Ong, T.A. (2018), Practical updates in medical therapy for advanced and metastatic renal cell carcinoma. Urological Science, 29 (3), 120-8. (ISI-Indexed)
  • Edmund Chiong, Declan G. Murphy, Hideyuki Akaza, Nicholas C. Buchane, Byung Ha Chung , Ravindran Kanesvaran, Makarand Khochikar, Jason Letran, Bannakij Lojanapiwat, Chi-Fai Ng, Teng Ong, Yeong-Shiau Pu, MARNIZA SAAD, Kathryn Schubach, Levent Turkeri, Rainy Umbas, Vu Le Chuyen, Scott Williams, Ding-Wei Ye, ANZUP Cancer Trials Group and Ian D. Davis. Management of patients with advanced prostate cancer in the Asia Pacific region: ‘real-world’consideration of results from the Advanced Prostate Cancer Consensus Conference (APCCC) 2017. BJU International, 2018. (ISI-Indexed)
  • Ina Shaliny Duraisamy, MARNIZA SAAD, Adlinda Alip. Single vs multiple fraction palliative radiotherapy for uncomplicated painful bone metastases treated at University of Malaya Medical Centre: A single institutional Malaysian experience. Aging Medicine, 2018;1:133–140. (SCOPUS-Indexed)
  • MARNIZA SAAD, Flora Li Tze Chong, Anita Zarina Bustam, Gwo Fuang Ho, Rozita Abdul Malik, Wan Zamaniah Wan Ishak, Vincent Chee Ee Phua, Mastura Md Yusof, Ning Yi Yap, Adlinda Alip. The efficacy and tolerability of scalp cooling in preventing chemotherapy‑induced alopecia in patients with breast cancer receiving anthracycline and taxane‑based chemotherapy in an Asian setting. Ind Journal of Cancer, 2018;157-161. (ISI-Indexed)

2017
  • Moradi, F., Ung, N.M., Khandaker, M.U., Mahdiraji, G.A., SAAD, M., Malik, R.A., Bustam, A.Z., Zaili, Z. and Bradley, D.A.,(2017). Monte Carlo skin dose simulation in intraoperative radiotherapy of breast cancer using spherical applicators. Physics in medicine and biology. 62, 6550-66. (ISI-Indexed)
  • Bhoo-Pathy NT, Inaida S2, Tanaka S, Taib NA3, Yip CH, SAAD M, Kawakami K, Bhoo-Pathy N. Impact of adjuvant chemotherapy on survival of women with T1N0M0, hormone receptor negative breast cancer. Cancer Epidemiology Jun 2017;48:56-61. doi: 10.1016/j.canep.2017.03.007. Epub 2017 Apr 1. (ISI-Indexed)
  • Karim Fizazi, M.D., Ph.D., NamPhuong Tran, M.D., Luis Fein, M.D., Nobuaki Matsubara, M.D., Alfredo Rodriguez‑Antolin, M.D., Ph.D., Boris Y. Alekseev, M.D., Mustafa Özgüroğlu, M.D., Dingwei Ye, M.D., Susan Feyerabend, M.D., Andrew Protheroe, M.D., Ph.D., Peter De Porre, M.D., Thian Kheoh, Ph.D., Youn C. Park, Ph.D., Mary B. Todd, D.O., and Kim N. Chi, M.D., for the LATITUDE INVESTIGATORS*. Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer. New Eng J Med, 2017. (ISI-Indexed)

2016
  • Nahjatul Kursyiah Abd Ghafar, Adlinda Alip, Teng Aik Ong, Ning Yi Yap, MARNIZA SAAD. Efficacy, safety, and prognostic indicators of first-line sunitinib in patients with metastatic renal cell carcinoma: A single center experience. Journal of Cancer Research & Therapeutics, Aug 2016. (ISI-Indexed)

2015
  • Nor Faissal Yasin1, Vivek Ajit Singh, MARNIZA SAAD, Effat Omar. Which is the best method of sterilization for recycled bone autograft in rabbit. BMC Cancer (2015) 15:289. (ISI-Indexed)
  • Vincent Chee Ee Phua, Wei Quan Wong, Pei Lin Tan, Anita Zarina Bustam, MARNIZA SAAD, Adlinda Alip, Wan Zamaniah Wan Ishak. Capecitabine Pattern of Usage, Rate of Febrile Neutropaenia and Treatment Related Death in Asian Cancer Patients in Clinical Practice (ISI-Indexed)
  • Weng Heng Tang, Adlinda Alip, MARNIZA SAAD, Vincent Chee Ee Phua, Hari Chandran, Yi Hang Tan,Yan Yin Tan, Voon Fong Kua, Mohamed Ibrahim Wahid, Lye Mun Tho. Prognostic Factors in Patients with Non-small Cell Lung Carcinoma and Brain Metastases: a Malaysian Perspective (ISI-Indexed)
  • Yasin, N. F., Singh, V. A., Saad, M., & Omar, E. (2015). Which is the best method of sterilization for recycled bone autograft in limb salvage surgery: a radiological, biomechanical and histopathological study in rabbit. BMC cancer, 15(1), 289. (Tier 2, Impact Factor = 3.362) (ISI-Indexed)

2014
  • WI Wan Zamaniah, MY Mastura, CE Phua, A Adlinda, S MARNIZA, AM RozitaDefinitive Concurrent Chemoradiotherapy in Cervical Cancer - a University of Malaya Medical Centre Experience. Asian Pac J Cancer Prev, 15 (20), 8987-8992 (ISI-Indexed)
  • M.Y. Mastura, S. MARNIZA, W.I. Wan Zamaniah, P. Vincent, A.M. Rozita, A. Adlinda, G.F. Ho. P0140 Second line aflibercept/folfiri chemotherapy in metastatic colorectal cancer in a single institution in a south east asian country: A case series. European Journal of Cancer 05/2014; 50:e48-e49. (ISI-Indexed)
  • M.Y. Mastura, S. MARNIZA, W.I. Wan Zamaniah, P. Vincent, A.M. Rozita, A. Adlinda, G.F. Ho. P0140 Second line aflibercept/folfiri chemotherapy in metastatic colorectal cancer in a single institution in a South East Asian country: A case series. European Journal of Cancer 05/2014; 50:e48-e49. DOI: 10.1016/j.ejca.2014.03.184 (ISI-Cited Publication) (ISI-Indexed)

2012
  • Phua Chee Ee, Anita Zarina Bustam,Mastura Md Yusof, MARNIZA SAAD,Yip Cheng-Har, Nor Aishah Taib, Ng Char Hong, Teh Yew Ching 2012. Risk of Treatment Related Death and Febrile Neutropaenia with Taxane-Based Adjuvant Chemotherapy for Breast Cancer in a Middle Income Country Outside a Clinical Trial Setting. Asia Pacific Journal of Cancer Prevention; 13(9), 4623-4626. (ISI-Indexed)
  • Chee Ee Phua, Anita Zarina Bustam, Mastura Md Yusof, MARNIZA SAAD, Cheng-Har Yip, Nor Aishah Taib and Char Hong Ng. 2012 Risk of treatment related death (TRD) with adjuvant chemotherapy for breast cancer: A study in University Malaya Medical Centre (UMMC). Journal of Cancer Therepeutics & Research 1: 13 (SCOPUS-Indexed)

2010
  • Rozita AM, MARNIZA S, Mastura MY, Wan Zamaniah WI, Yip CH, Taib NA, 2010. Patterns of breast cancer relapse at University of Malaya Medical Centre, JUMMEC 2010:13 (1):24-32. (SCOPUS-Indexed)
  • Ajit Singh V, Nagalingam J, SAAD M, Pailoor J, 2010. Which is the best method of sterelisation of tumour bone for reimplantation? A biomechanical and histopathological study. Bio-Medical Engineering OnLine 2010, 9:48. (ISI-Indexed)
  • Hoong-Yin Chong, Nur Aishah Taib, Sanjay Rampal, MARNIZA SAAD, Anita Zarina Bustam, Cheng-Har Yip. Treatment options for locally advanced breast cancer - experience in an Asian tertiery hospital. APJCP, 11:2010;1-5. (ISI-Indexed)
  • Lau Peng Choong, Nur Aishah Mohd Taib, Sanjay Rampal, MARNIZA SAAD, Anita Zarina Bustam, Yip Cheng Har. High tumour stage and margin clearance are still important prognostic factors for post-mastectomy locoregional recurrence in Malaysia. APJCP,11:2010;1409-1416. (ISI-Indexed)
Proceeding

2018
  • Hui Shan Tan, Alvin Seng Cheong Wong, Kian Tai Chong, Siew Wei Wong, MARNIZA SAAD, Chi_Fai Ng, Shigeo Horei, Pichai Chansriwong, Min-Han Tan, Chee-Keong Toh, Quan Sing Ng, Kiat Hon Lim, Liang Seah Tay, Whee Sze Ong, Ravindran Kanesvaran. AR-V7 in Asian patientts with metastatic CRPC : A multinational, multicentre study. Journal of Clinical Oncology. February 2018;36(6_suppl):TPS401-TPS401. (ISI-Indexed)

2017
  • Audi Adawiah Sulaiman Shah*, Khairiyah Sidek, Syafirin Ab Sani, Najihah Abu Bakar, Ardif Damiri, Rizma Mohd Zaid, MARNIZA SAAD, Adlinda Alip. Efficacy and safety of pazopanib in advanced renal cell carcinoma treated at University Malaya Medical Centre (UMMC). Adv Mod Oncol Res 2017; 3(6):301. http://dx.doi.org/10.18282/amor.v3.i6.282. (ISI-Indexed)
  • J Lim, N Shariff, M SAAD, A Alip, T Ong, S Lechmiannandan, F Ahmayuddin, A Mathew, FCL Tze (2017). Abiraterone in metastatic castrate resistant prostate cancer: outcome and tolerance in real-world setting. BJUI International Supplement S4: S10-11. (ISI-Indexed)

2016
  • JY-Y Khoo, A Alip, M SAAD, TA Ong. Treatment outcomes of patients with Metastatic Castrate Resistant Prostate Cancer (MCRPC) on first line docetaxel chemotherapy at University Malaya Medical Centre. BJUI Nov 2016, 118, Supplement 3, 1-19. (ISI-Indexed)
  • SN Masyitah, AHA Razack, TA Ong, M SAAD, A Alip. The unusual kid on the block:Primary Renal Ewing Sarcoma. BJUI Nov 2016, 118, Supplement 3, 1-19. (ISI-Indexed)
  • S Nisha, AS Syadwa,S Patricia, S Kisha, MJ Chan, TA Ong, S MARNIZA, A Adlinda. Real-World experience with abiraterone in metastatic castrate resistant prostate carcinoma in University Malaya Medical Centre. BJUI 2016, 118, Supplement 3, 1-19. (ISI-Indexed)

2015
  • NK Abd Ghafar, A Alip, TA Ong, M Saad. Efficacy and safety of first line sunitinib in patients with metastatic renal cell cancer: a Malaysian experience from a single tertiary centre. BJU International 2015, 116, Supplement 4, 1-27. (ISI-Indexed)
  • J Lim, N Bhoo-Pathy, A Alip, M SAAD, TA Ong, AHA Razack. The prostate cancer profile in multiethnic Asian men. BJU International 2015, 116, Supplement 4, 1-27. (ISI-Indexed)

2014
  • MY Mastura, S MARNIZA, WI Wan Zamaniah, P Vincent, AM Rozita, A Adlinda, GF Ho. Second line aflibercept/folfiri chemotherapy in metastatic colorectal cancer in a single institution in Sute East Asian country : a case series. Asian Oncology Summit, Apr 2014. (Non-ISI/Non-SCOPUS)

2013
  • Mastura Md Yusof, Suhana Yusak, Wan Zamaniah Wan Ishak, Rozita Abdul Malik, Adlinda Alip, Vincent Phua Chee Ee, Marniza Saad. Outcome of Routine Radioiodine Ablation for Differentiated Thyroid Cancer in an Academic Institution. APCC Oct 2013. in Kuala Lumpur, Malaysia, 22nd Asia Pacific Cancer Confefence, 31 Oct 2013 to 02 Nov 2013, APCC, (International) (Non-ISI/Non-SCOPUS)

2012
  • MARNIZA SAAD, Tang Weng Heng, Marfu'ah Eezamuddeen. Ten year survival in metastatic renal cell carcinoma treated with repeated local treatment and sequential systemic therapy. PD-244,2012. Asian Clinical Oncology Society Conference Proceeding, 13-15 Jun 2012. (Non-ISI/Non-SCOPUS)
Others

2014
  • Lee PY, Ng CJ, Lee YK, Cheong AT, Khatijah A, Ong TA, Azad AR, MARNIZA S, Adlinda A, Nuratiqah AJ. Making the choice :deciding what to do about early stage prostate cancer.ISBN No: 978-967-960-351-4 

2011
  • Coping with Chemotherapy : Information Booklet for Patients Undergoing Chemotherapy, 2011. 
  • Systemic Therapy of Cancer updated 2nd Edition 2011. Ministry of Health, 2011. 

2008
  • Systemic Therapy of Cancer 2nd Edition. Ministry of Health, 2008. 

AREAS OF RESEARCH
(Project title), (Role), (From)-(Until), (Level), (Source).


  • MAGNITUDE Study : A phase 3 randomized, placebo-controlled, double-blind study of niraparib in combination with abiraterone acetate and prednisolone versus abiraterone acetate and prednisolone for treatment of subjects with metastatic prostate cancer., Principal Investigator(PI), 2019 - 2022, International Funding, (International)
  • Phase II Randomized Controlled Trial Tiger Milk Mushroom (TM02) in Patients with Breast Cancer, Consultant, 2019 - 2021, Private Funding, (National)
  • Phase III, multicentre, randomised, placebo-controlled study of atezolizumab (anti PD-L1 antibody) as monotherapy and in combination with platinum-based chemotherapy in patients with untreated locally advanced or metastatic urothelial carcinoma. (WO30070 / IMvigor130), Principal Investigator(PI), 2017 - 2020, Private Funding, (International)
  • A Phase III, Randomized, Open-Label Clinical Trial of Pembrolizumab (MK-3475) versus Paclitaxel in Subjects with Advanced Gastric or Gastroesophageal Junction Adenocarcinoma who Progresses after First-Line Therapy with Platinum and Fluoropyrimidine, Co-Investigator, 2016 - 2017, Private Funding, (National)
  • AR-V7 Splice variant in Asian patients with castration resistant prostate cancer (CRPC), Principal Investigator(PI), 2016 - 2019, Private Funding, (International)
  • A Phase 2 Clinical Trial of Pembrolizumab in Subjects with advanced/ unresectable or metastatic urothelial cancer., Principal Investigator(PI), 2015 - 2020, Industry, (International)
  • Studies of Epigenetic Changes in Circulating Tumor Cells in Breast Cancer, Co-Investigator, 2014 - 2015, Nova Satra Health, (National)
  • A Prospective Cohort Study of Patients with Malignant Cord Compression, Co-Investigator, 2014 - 2015, NUS, (International)
  • GDC-0068 Study (JAGUAR) A Randomized, Phase II, Placebo-Controlled Study of GDC-0068, An Inhibitor to Akt, In Combination with Fluoropyrimidine plus Oxaliplatin in Patients with Locally Advanced or Mestatatic Gastric or Gastroesophageal Junction Adenocarcinoma, Co-Investigator, 2014 - 2015, Genetech Inc, (International)
  • A Phase III Randomised, Double-Blind,Parallel Group, Multicentre Study to Compare the Efficacy, Safety, Pharmacokinetics and Immunogenicity between SB3 (proposed trastuzumab biosimilar) and Herceptin in Women with Newly Diagnosed HER2 Positive Early or Locally Advanced Breast Cancer in Neoadjuvant Setting, Co-Investigator, 2014 - 2016, Samsung Bioepis, (International)
  • A RANDOMIZED, MULTICENTRED. OPEN LABEL PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TRASTUZUMAB EMTAMSINE VERSUS TRASTUZUMAB PLUS DOCETAXEL AS FIRST LINE TREATMENT OF PATIENTS WITH HER2-POSITIVE PROGRESSIVE OR RECURRENT LOCALLY ADVANCED OR METASTATIC BREAST CANCER, Co-Investigator, 2014 - 2018, Roche, (National)
  • Prospective study of UDP-gluconoryltransferase (UGT) 2B17 genotype as a predictive marker of exemestane pharmacokinetics and pharmacodynamics in Asian women with hormone receptor-positive advanced breast cancer, Co-Investigator, 2013 - 2015, NONE, (National)
  • YO28322(MetGastric Study) A Randomized, Phase III, Multicenter, Double-Blind, Placebo-Controlled Study Evaluating The Efficacy and Safety of Onartuzumab (MetMAb) in Combination with 5-Fluorocil, Folinic Acid, and Oxaliplatin (mFOLFOX6) in Patients with Metastatic HER2-Negative, Met-Positive Gastroesophageal Cancer, Co-Investigator, 2013 - 2017, Roche, (National)
  • PROSPER A multinational, Phase 3, Randomized, Double blinde, Placebo controlled, Efficacy and Safety of Enzalutamide in Patient With Nonmetastatic Castration-Resistant Prostate Canncer, Co-Investigator, 2013 - 2018, Medivation and Astella , (International)
  • A randomised double-blind comparative study of Zytiga (abiraterone acetate) plus low dose prednisolone plus androgen deprivation therapy (ADT) versus ADT alone in newly diagnosed subjects with high risk metastatic hormone-naive prostate cancer (mHNPC). LATITUDE, Principal Investigator(PI), 2012 - 2018, Janssen Cilag, (International)
  • A phase 3, randomized, double-blind, placebo-controlled study of abiraterone acetate (JNJ-212082) plus prednisone in asymptomic or mildly symptomatic patients with metastatic castration-resistant prostate cancer, Principal Investigator(PI), 2012 - 2015, Janssen Cilag (Johnson & Johnson), (National)
  • A PHASE II DOUBLE BLIND, PLACEBO CONTROLLED, RANDOMIZED STUDY OF GDC-0941 OR GDC-0980 WITH FULVESTRANT VERSUS FULVESTRANT IN METASTATIC BREAST CANCER IN PATIENTS RESISTANT TO AROMATASE INHIBITOR THERAPY., Co-Investigator, 2012 - 2014, GENETECH INC, (International)
  • A Randomised Multicentre, Adaptive Phase II/III Study to Evaluate the Efficacy and Safety of Trastuzumab Emtansine 1(T-DM1) versus taxane (Docetaxel or Paclitaxel)in Patients with Previouly Treated Locally Advanced or Metastatic HER2 Positive Gastric Cancer, Including Adenocarcinoma of the Gastroesophageal Junction (GATSBY), Co-Investigator, 2012 - 2014, NONE, (International)
  • ABI-PRO- 3002 A phase 3, randamized, double-blind,placebo-controlled study of abiraterone acetate)JNJ-212082) plus prednisone in asymtomic ormildly symptomatic patients with metastaticcastration-resistant prostate cancer, Principal Investigator(PI), 2012 - 2017, Quintiles Janseen Cilaq, (National)
  • B027952 (GATSBY Study) A randomized, multicenter, adaptive phase II/III study to evaluate the efficacy and safety of trastuzumab emtansine (T-DM1) versus taxane (docetaxel or paclitaxel) in patients with previously treated locally advanced or metastatic HER2-positive gastric cancer, including adenocarcinoma of the gastroesophageal function., Co-Investigator, 2012 - 2015, Roche, (National)
  • Lapatinib study Phase II open-labelstudy of preoperativeweeklypac55 litaxel and carboplatinwithlapatinib (Tykerb ) in patientswith ErB2-positive stage I-III Breastc ncer, Co-Investigator, 2011 - 2013, High Impact Research (HIR), (National)
  • MT-102-2001 : (Myotec Study) A multicentre, randomized, double-blind, placebo- controlled, dose-finding phase II clinical study to evaluate the efficacy of two different doses of MT-102 administered over a sixteen week period in subjects with cachexia related to stage III and IV non small-cell lung cancer and colorectal cancer., Co-Investigator, 2011 - 2013, Psioxus Therapeutic Limited , (International)
  • Multicentre, single-arm, open label, clinical trial intended to provide early access to cabazitaxel in patients with metastatic hormone refractory prostate cancer previously treated with a docetaxel-containing regimen and to document safety of cabazitaxel in these patients., Principal Investigator(PI), 2011 - 2012, Sanofi-Aventis, (International)
  • ASCOLTAspirin in treating patients with Dukes stage C colon or rectal cancer, or high risk Dukes stage B colon cancer that has been completely removed by surgery., Co-Investigator, 2010 - 2017, NCC Singapore, (International)
  • Linifanib vs sorafenib for upfront treatment of advanced hepatocellular carcinoma, Co-Investigator, 2010 - 2012, Abbott, (International)
  • ATHENA A phase IV open label study of bevacizumab plus taxane monotherapy or in combination for the first line treatment of patients with locally recurrent or metastatic breast cancer., Principal Investigator(PI), 2009 - 2011, Roche, (International)
  • Nasopharyngeal Carcinoma Treatment Outcome Database., Consultant, 2009 - 2015, Ministry of Health, (National)
  • 2009AG-013736 (Axitinib) as Second Line Therapy for Asian Patients with Metastatic Renal Cell Cancer, Principal Investigator(PI), 2009 - 2011, Pfizer, (International)
  • LUME-Lung 2 An international, multi-centre phase III randomised controlled trial for second line treatment of recurrent, advanced non-small cell lung cancer, comparing pemetrexed + placebo versus pemetrexed + BIBF1120 (a multi-targeted tyrosine kinase inhibitor)., Co-Investigator, 2009 - 2012, Boehringer-Ingelheim, (International)
  • SAVE-ONCO: A multinational, randomized, double- blind, placebo-controlled study to evaluate the efficacy and safety of AVE5026 in the prevention of venous throboembolism (VTE) in cancer patients at high risk for VTE and who are undergoing chemotherapy, Co-Investigator, 2008 - 2008, Sanofi-Aventis, (International)
  • An international multi-centre phase III randomised controlled trial of first line treatment of advanced renal cell carcinoma, comparing bevacizumab + interferon-alpha versus bevacizumab + torisel., Principal Investigator(PI), 2008 - 2012, Wyeth, (International)
  • NPC Study An open labeled, multicentre, randomized phase II trial of combination gemcitabine and carboplatin chemotherapy in patients with metastatic or recurrent nasopharyngeal carcinoma., Co-Investigator, 2008 - 2011, Cancer Research Centre, Ministry of Health, Malaysia, (National)
  • Induction and concurrent chemoradiation with cetuximab for treatment of locally advanced Nasopharyngeal Carcinoma, Co-Investigator, 2008 - 2012, Geran Penyelidikan Universiti Malaya (UMRG), (National)
  • A prospective controlled study on the role of Scalp Hypothermia to prevent chemotherapy-induced Alopecia in patients with breast cancer receiving anthRacycline and taxanE-based chemotherapy. (SHARE Study), Principal Investigator(PI), 2008 - 2010, Short Term Research Fund (Vote F)(PJP), (National)
  • A phase 3 multicentre, randomised, placebo- controlled trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy regimens in subjects with previously treated metastatic breast cancer., Principal Investigator(PI), 2007 - 2010, Genentech, (National)

CONSULTATION PROJECT/CONSULTANCY
(Project title), (Role), (From)-(Until), (Organisation).


  • Roche : Asia-Pacific Regional Meeting - Together We Maximise Clinical Outcome of mRCC Patients., 2018-2018, Roche
  • MSD : Pembrolizumab in Advanced Urothelial Carcinoma, Jan 2018, Kuala Lumpur., 2018-2018, MSD
  • Novartis : mRCC Side Effect Management of Targeted Therapy, Internal Training, Jul 2018, Kuala Lumpur., 2018-2018, Novartis
  • J&J : Advanced Prostate Cancer Treatment Approaches, Oct 2018, Hanoi., 2018-2018, J&J
  • Astellas : Advanced Prostate Cancer Management, Internal Training, May 2018, Kuala Lumpur., 2018-2018, Astellas
  • J&J : ACE 6 Steering Committee Meeting, 10 Mar 2017, MALAYSIA., 2017-2017, J&J
  • Eisai : Renal Cell Carcinoma, ESCON 2017 - 18 Mar 2017, TAIWAN., 2017-2017, Eisai
  • Roche : Malaysian Urothelial Carcinoma Advisory Board Meeting 25 Feb 2017, MALAYSIA., 2017-2017, Roche
  • Novartis : Ribociclib Advisory Board Meeting 7 Dec 2017, MALAYSIA., 2017-2017, Novartis
  • MSD : Malaysian Genitourinary Cancer Advisory Board Meeting 28 Oct 2017, MALAYSIA., 2017-2017, MSD
  • Eisai : Advisory Board Meeting for Lenvatinib in Advanced Renal Cell Cancer 19 Mar 2017, TAIWAN., 2017-2017, Eisai
  • LASER RCC - Case Study on Sunitinib First Line, 2016-2016, Pfizer Oncology
  • Asian Gastric Cancer Expert Meeting, 2016-2016, Eli Lilly
  • Asia-Pacific Bladder Cancer Expert Froum, 2016-2016, MSD
  • J&J : Treatment of Advanced Prostate Cancer : Putting Evidence into Clinical Practice, 2016, 2016-2016, Johnson&Johnson
  • Soft Tissue Sarcoma Advisory Board Meeting, 2016-2016, Eisai
  • Renal Cell Carcinoma Adboard Meeting, 2016-2016, Pfizer
  • Asian Sarcoma Consortium 2nd Meeting, 2016-2016, ASC
  • Johnson&Johnson : First Pros-Ova Malignancies Standalone Meeting., 2015-2015, Johnson&Johnson
  • Johnson&Johnson : 23rd Asia Pacific Cancer Conference APCC 2015 - Heterogeneity of Prostate Cancer A Guide to Treatment Choice, Indonesia., 2015-2015, Johnson&Johnson
  • Bayer : Prostate Cancer Adboard Meeting - Optimising Treatment for Prostate Cancer, Singapore., 2015-2015, Bayer
  • Janssen : Treatment of Metastatic Prostate Cancer - Newer Options. Brunei Cancer Symposium Feb 2015., 2015-2015, Janssen
  • Astellas : Prostate Cancer Advisory Board Meeting, Singapore., 2015-2015, Astellas
  • Johnson&Johnson : Prostate Cancer Seminar - Past Present & Future of Treatment, 2015-2015, Johnson&Johnson
  • Sanofi : Prostate Cancer Adboard - Accomplishment & Challenges in Prostate Cancer, Singapore., 2015-2015, Sanofi
  • Roche : Chemotherapy Training for Myanmar Nurses Apr 2015, 2015-2015, Roche Myanmar
  • Pfizer : RCC Advisory Board - Optimal Management of Renal Cell Carcinoma, Singapore., 2015-2015, Pfizer
  • Roche : Capecitabine Preceptorship for Myanmar Oncologists April 2015., 2015-2015, Roche Myanmar
  • Astella Adboard : Metastatic Castrate Resistant Prostate Cancer Expert Panel Meeting, 2014-2014, Astella
  • Sanofi : Asia Pacific Genitourinary Conference 2014, 2014-2014, Sanofi
  • Sanofi : SURF Meeting Jun 2014 : Prostate Cancer Plenary : Role of Chemotherapy & Optimal Sequencing of Therapy., 2014-2014, Sanofi
  • MARA : Cancer - The smart enemy. Decoding their strategies in order to win the cancer battlefield. Biology at its molecular level. MRSM BIOLOGY TEACHERS EDUCATION SUMMIT 2014, 19 May 2014 to 22 May 2014., 2014-2014, MARA Excellent Ventures Sdn Bhd
  • Kidney Cancer and Its Treatment Development, 2014-2014, Pfizer
  • Pfizer : SURF Meeting Jun 2014 : Renal Cancer Plenary : Evolution of Front Line Targeted Therapy & Management of Side Effects - A Survival Guide for Urologists., 2014-2014, Pfizer
  • Sanofi : SURF Meeting Jun 2014 : Prostate Cancer Plenary : Role of Chemotherapy & Optimal Sequencing in mCRPC., 2014-2014, Sanofi
  • Pfizer CME May 2014 Hospital Kuala Lumpur : A new second line treatment for mRCC. What does the evidence say, 2014-2014, Pfizer
  • Pfizer CME Apr 2014 Institut Kanser Negara : A new second line treatment for mRCC. What does the evidence say, 2014-2014, Pfizer
  • GSK : AOS Apr 2014 : Preventing SREs in Practice : How Early is Early in Patients with Bone Metatstases Professor Roger von Moos, Switzerland., 2014-2014, GSK
  • Eisai : AOS Apr 2014 : Metastatic Breast Cancer : What Can We Do Today For Patients Professor Michael Gnant, Vienna., 2014-2014, Eisai
  • Janssen CME : Clinical Conversations in mCRPC. Professor Charles Ryan, San Francisco., 2014-2014, Janssen
  • Bayer Adboard : Xofigo Adboard Meeting Apr 2014, 2014-2014, Bayer
  • MOH : Committee for Revision of National Chemotherapy Protocol Guidelines, 2014-2014, Ministry of Health Malaysia
  • Eisai : Beyond Conventional Treatment in Pre-Treated Metastatic Breast Cancer, 2013-2013, Eisai
  • Pfizer : POW-WOW RCC Symposium, 2013-2013, Pfizer Oncology
  • Sanofi : Asia Pacific Genito-Urinary Conference 2013, 2013-2013, Sanofi Oncology
  • Pfizer Adboard : Continuum of Care Expert Panel - Asia renal cell carcinoma advisory board meeting, 2013-2013, Pfizer Oncology
  • Sanofi : Management of Castrate Resistant Prostate Cancer, 2013-2013, Sanofi Oncology
  • Janssen : Training on new product abiraterone and treatment of metastatic castrate resistant prostate cancer., 2012-2012, Janssen
  • Janssen Adboard : Treatment of Prostate Cancer Adboard Meeting, 2012-2012, Janssen
  • Sanofi : Jevtana Media Launch - Treatment Paradigm Change for Castrate Resistant Prostate Cancer after Docetaxel Failure, 2012-2012, Sanofi Aventis
  • Pfizer : Hepatocellular Carcinoma and Gastric Cancer Adboard Meeting April 2012, 2012-2012, Pfizer Oncology
  • Davos : Gamma-delta tocotrienol : Phase One Dose Escalation and Pharmacokinetics Study on Castrate Resistant Prostate Cancer Patients, 2012-2012, Davos Life Science Pte Ltd
  • GSK Adboard : HER2+ HR+ metastatic breast cancer board meeting 2011., 2011-2011, GSK Oncology
  • UPM : Patient information article on cervical cancer for Cancer Resource and Education Center (CaRE) UPM., 2011-2011, University Putra Malaysia
  • Medical Nutrition Therapy for Cancer Patients., 2011-2011, Malaysian Dietitian Association
  • South East Asia Radiation Oncology Group (SEAROG)., 2011-2011, SEAROG
  • MOS : Prostate Cancer Symposium, Asia Pacific Cancer Conference 2011., 2011-2011, Malaysian Oncological Society
  • MOS : Asian Pacific Cancer Conference, Kuala Lumpur 2011., 2010-2010, Malaysian Oncological Society
  • Radiotherapy and Oncology Department Plan for Health Metropolis Project., 2010-2010, Health Metropolis
  • MOH : Guidelines for management of brachytherapy for prostate cancer using permanently implanted radioactive sources 2010., 2010-2010, Bahagian Perkhidmatan Kejuruteraan
  • Novartis Adboard : mTOR inhibitors in metastatic renal cell carcinoma., 2010-2010, Novartis Oncology
  • MOH : National Cancer Patient Registry (NCPR) : A patient registry (clinical database) to evaluate the health outcomes of patients undergoing treatment for cancers in Malaysia., 2009-2009, Ministry of Health Malaysia
  • MOH : Workshop on Systemic Therapy of Cancer protocol for Malaysia, 2007-2007, Kementerian Kesihatan Malaysia

AWARDS AND RECOGNITIONS
(Name of Award), (Awarding Institution), (Year Awarded), (Level).


  • Certificate of Appreciation - Huna (Ho Chi Minh Urology and Nephrology Association) Annual Meeting - Banmethuot, Vietnam - June 2019, Huna Vietnam, 2019, (International)
  • Certificate of Appreciation - Prostate Cancer Meeting - Cho Ray Hospital, Vietnam June 2019., Cho Ray Hospital, Ho Chih Minh, Vietnam, 2019, (International)
  • Certificate of Appreciation : Oncology Colloquium 2-3 Feb 2018, UM., Malaysian Medic International, 2018, (National)
  • Certificate of Appreciation : Sarcoma Mdt Preceptorship, 14-15 Jul 2017, Singapore., National Cancer Centre, Singapore., 2017, (International)
  • Certificate of Appreciation : Masterclass in Systemic Cancer Therapy (Msct2017), 4-5 March 2017, Ummc., Ummc, 2017, (National)
  • Certificate of Appreciation : Mmi Specialising Opportunities Symposium 2 -Specialising in Oncology, Mmi, 29-30 Apr 2017, Kuala Lumpur., Mmi (Malaysian Medics International), 2017, (National)
  • Certificate of Appreciation, Malaysian Oncological Society : Ascomos 2017, Mos, 2017, (National)
  • Anugerah Perkhidmatan Cemerlang Universiti Malaya Tahun 2016., University Malaya, 2017, (University)
  • Best Lecturer for Clinical Oncology Session 2015/2016., University Malaya, 2017, (University)
  • Excellence Service Award, University Malaya, 2017, (University)
  • Letter of Appreciation, University Malaya, 2016, (University)
  • Certificate of Appreciation, College of Surgeons Malaysia, 2016, (National)
  • Certificate of Appreciation, Malaysian Urological Association, 2016, (National)
  • Certificate of Appreciation, Malaysian Oncological Society, 2016, (National)
  • Certificate of Appreciation, Malaysian Urological Association, 2016, (National)
  • Certificate of Appreciation, Malaysian Orthopaedic Association, 2016, (National)
  • Certificate of Appreciation : Capecitabine Preceptorship April 2015., Ummc, 2015, (International)
  • Featured as An Expert Panel in 23rd Asia Pacific Cancer Conference Bulletin : Heterogeneity of Prostate Cancer - a Guide to Treatment Choice., Apcc, 2015, (International)
  • Certificate of Appreciation : Invited Panel At The First Ummc Breast Cancer Public Forum 18 Oct 2014., Ummc, 2014, (National)
  • Certificate of Appreciation : Scientific Committee for Colorectal Cancer Workshop 29 March 2014., Department of Clinical Oncology Ummc, 2014, (University)
  • Certificate of Appreciation : Invited Faculty in The Section of Uro-Oncology Forum 2014 7-8 June 2014, Mua, 2014, (National)
  • Expert Panel On National Radio Station Bfm, The Bigger Picture - Kidney Cancer and Its Treatment Development. Http://WWW.Bfm.My/Marniza-Saad-Kidney-Cancer.Html , (National), 26-Jun-14 Until 26-Jun-14, Bfm Radio, 2014, (National)
  • Certificate of Appreciation : Coordinator for Oncology Track At Musculoskeletal Imaging Conference, College of Radiology Malaysia, 2013, (International)
  • Expert Panel in Health and Beauty Magazine On`Targeted Therapies for Cancer Care'., Health and Beauty, 2013, (National)
  • Expert Panel in Health Today Magazine On 'Treating Prostate Cancer', Health Today, 2013, (National)
  • Certificate of Appreciation : Scientific Committee and Chair At Ascomos 2013, Malaysia Oncology Society, 2013, (International)
  • Certificate of Excellent Service, University Malaya, 2011, (University)
  • Sijil Perkhidmatan Cemerlang., University Malaya, 2011, (University)
  • Expert Panel On Helo Malaysia At Bernama Tv : Breast Cancer., Bernama Tv, 2009, (National)
  • Sijil Perkhidmatan Cemerlang Kepada Pesakit., University Malaya Medical Centre., 2008, (University)

PRESENTATIONS
(Title), (Event), (Date Presented), (Organiser), (Level).


INVITED SPEAKER
  • New Moves in Breast Cancer : AntiVEGF & AntiHER2 Therapy, Annual Scientific Meeting College of Surgeons : Detecting Cancer Earlier, 2007-06-08 to 2007-06-10, College of Surgeons , (National)
  • Radiotherapy in Gynaecological Cancers : An Overview, Emerging Themes in Gynaecology Oncology The Way Forward, 2008-08-15 to 2008-08-17, Department of Obstetrics and Gynaecology, University Malaya, (National)
  • Management of Acute and Late Side-effects of Radiotherapy, Medical Imaging and Radiation Therapy Updates , 2009-06-25 to 2009-06-26, MSR, (National)
  • Adjuvant Breast Cancer : The time to change, Johore Scientific Meeting, 2009-07-20 to 2009-07-22, KKM, (National)
  • The issues on follow-up and complications of radiotherapy in nasopharyngeal and laryngeal cancers., MOS-MSOHNS Joint Meeting : New Frontier in the Management of Nasopharyngeal and Laryngeal Cancer , 2009-10-10 to 2009-11-11, MOS-MSOHNS of Malaysia, (National)
  • Molecular targeted therapy in renal cell carcinoma., First MOS-EOF Conference : Hands in hands in Cancer., 2010-05-01 to 2010-05-02, MOS, MUA, EOF, (International)
  • RCC Case presentation, 1st MOS-MUA Uro-Onccology Meeting : Kidney Cancer Series, 2010-07-17 to 2010-07-18, MOS, MUA, Pfizer, (National)
  • Systemic Therapy for Cancer, Oncology Nursing Seminar, 2010-09-28 to 2010-09-29, UM, (University)
  • Improving outcome of patients with bone metastases., Oncology Free Standing Symposium 1 Oncology., 2010-11-12 to 2010-11-12, MOS Novartis, (National)
  • mTOR inhibitor : 1 year on. , Oncology Free Standing Symposium 1 Oncology, 2010-11-12 to 2010-11-13, MOS and Novartis, (National)
  • Medical Management of Bone Metastasis, International Metastatic Bone Disease Course, 2011-05-20 to 2011-05-21, UM, (International)
  • Case study on locally advanced prostate cancer, Art of Uro-Oncology, 2012-02-18 to 2012-02-19, Malaysian Oncology Society, Malaysian Urological Association, Singapore Urological Association, (International)
  • Timing of surgery and systemic therapy for mRCC, MUA-MOS-SUS Conference 2012, 2012-11-23 to 2012-11-25, MUA and MOS, (International)
  • Clinical Biomarker to Sunitinib Efficacy, POW WOW RCC Symposium, 2013-04-20 to 2013-04-21, Pfizer Oncology, (National)
  • Tripartite Track : New Frontier in Early Breast Cancer : Hormonal Therapy - What's New?, 2nd AMM-ASM-HKAM Tripartite Congress & 4th Singapore-Malaysia Congress of Medicine, 2013-08-23 to 2013-08-24, AMM, ASM, HKAM, (International)
  • Management of Castrate Resistant Prostate Cancer, Aseptic Dispensing Course 2013, 2013-11-10 to 2013-11-10, PENSMA, (International)
  • Management of Chemotherapy Side Effects, Aseptic Dispensing Course 2013, 2013-11-11 to 2013-11-11, PENSMA, (International)
  • A new second line treatment for mRCC : what does the evidence say?, Lunch CME at Institut Kanser Negara, Putrajaya, 2014-04-30 to 2014-04-30, Pfizer Oncology, (National)
  • A new second line treatment in mRCC : what does the evidence say?, Lunch CME at HKL, 2014-05-12 to 2014-05-12, Pfizer Oncology, (National)
  • Cancer : The smart enemy. Decoding their strategies in order to win the cancer battlefield. Biology at its molecular level., MRSM BIOLOGY TEACHERS EDUCATION SUMMIT 2014, 2014-05-19 to 2014-05-22, MRSM (MARA), (National)
  • Expanding Treatment Options in mRCC and Adverse Event Management, Lunch CME at Hospital Universiti Sains Malaysia, Kubang Kerian, 2014-09-03 to 2014-09-03, Pfizer Oncology, (National)
  • Principles of Radiotherapy and Chemotherapy in Sarcoma, Orthopaedic Oncology Intensive Course 2014, 2014-10-11 to 2014-10-11, Orthopaedic Department, UM, (University)
  • Why Do I Need Chemotherapy - Factors that Affect Outcome., The First UMMC Breast Cancer Public Forum, 2014-10-18 to 2014-10-18, Breast Cancer Resource Center UMMC, (National)
  • Treatment of Metastatic Prostate Cancer : Recent Updates., ESMO-MOS Conference 2015, 2015-01-23 to 2015-01-25, Malaysian Oncology Society, European Society of Medical Oncology, (International)
  • Treatment of Metastatic Prostate Cancer - Newer Options., The Brunei Cancer Centre Prostate Cancer Symposium, 2015-02-14 to 2015-02-15, The Brunei Cancer Centre, Johnson & Johnson, (International)
  • Radiotherapy Contouring for Prostate Cancer , Radiotherapy Contouring Course, 2015-02-27 to 2015-02-27, Universiti Kebangsaan Malaysia Medical Centre, University Malaya Medical Centre, (National)
  • Role of Radiotherapy and Chemotherapy in Cancerous Wounds and Stoma., Malaysian Enterostomal Therapy Nursing Educational Programme (Malaysian ETNEP), 2015-03-19 to 2015-03-19, University Malaya Medical Centre, (International)
  • Oral Chemotherapy, Xeloda Preceptorship 4th for Myanmar Nurses, 2015-04-06 to 2015-04-08, UMMC & Roche Myanmar, (International)
  • Planning and Managing Toxicities of Xeloda Treatment., Xeloda Preceptoship 3rd for Myanmar Oncologists, 2015-04-13 to 2015-04-15, UMMC & Roche Myanmar, (International)
  • Breast Cancer : Conventional Treatment, Recurrence and Metastasis, Reach to Recovery : A training workshop for breast cancer survivors, 2015-05-09 to 2015-05-09, Candy Girls UMMC, (National)
  • Current Trend in Oncology Management and Survival., 45th Malaysian Orthopaedic Association Annual Scientific Meeting 2015 : Current Trend and the Future in Orthopaedics., 2015-05-22 to 2015-05-24, Malaysian Orthopaedic Association, (International)
  • Heterogeneity of Prostate Cancer : Guide to Treatment Choice., The 23rd Asia Pacific Cancer Conference (APCC) 2015 : Cancer Care for All - From Prevention to Palliation., 2015-08-20 to 2015-08-22, Indonesian Society of Oncology, APFOC, UICC, (International)
  • Sarcoma : Targeted Therapy and Survival, Orthopaedic Oncology and Reconstructive Course, 2015-08-26 to 2015-08-27, Universiti Sains Malaysia, (National)
  • Role of Chemotherapy & Radiotherapy in Cancer and Cancer-related Stoma., Enterostomal Therapy Nursing Education Programme 2016, 2016-03-24 to 2016-03-24, UMMC, (National)
  • Oncological Treatment : To Give or Not To Give? That is the Question., Malaysian Hospice Congress, 2016-04-22 to 2016-04-24, Malaysian Hospice Council, (International)
  • Shared Decision Making, Pre-Congress Workshop College of Surgeon Annual Scientific Meeting - Masterclass in Communication, 2016-05-11 to 2016-05-11, College of Surgeons Malaysia, (International)
  • Optimising Care in Metastatic Renal Cancer - Case Discussion., Leadership and Scientific Exchange Regional Series (LASERS), 2016-05-18 to 2016-05-18, Pfizer Oncology, (International)
  • Chemotherapy and Targeted Therapy in Soft Tissue Sarcoma : Can We Improve Survival?, 46th Malaysian Orthpaedic Association Annual Scientific, 2016-05-25 to 2016-05-28, MOA, (International)
  • Chemotherapy & Targeted Therapy in Soft Tissue Sarcoma : Can We Improve Outcome Further?, 46th Malaysian Orthopaedic Association Annual Scientific Meeting, 2016-05-27 to 2016-05-27, MOA, (International)
  • Shared Decision Making, Onco-Lead Workshop 2016, 2016-08-20 to 2016-08-20, Dept of Clinical Oncology UMMC, (National)
  • Optimal Sequencing in mCRPC, Management of Castrate Resistant Prostate Cancer, 2016-09-30 to 2016-09-30, Johnson&Johnson, (National)
  • Management of Metastatic Castrate Resistant Prostate Cancer, Focus Group Meeting, 2016-10-01 to 2016-10-01, Johnson&Johnson, (National)
  • Metastatic Prostate Cancer : What are The Options?, Together Let's Fight Prostate Cancer, 2016-10-01 to 2016-10-01, Prostate Cancer Support Group, (National)
  • Prostate Cancer After Preliminary Treatment : What Next?, Together Let's Fight Prostate Cance, 2016-10-01 to 2016-10-01, Prostate Cancer Support Group, (National)
  • Intraoperative Radiotherapy - A New Technique in Malaysia., Breast Cancer Public Forum, 2016-10-09 to 2016-10-09, UMMC, (National)
  • (1) Novel Agents in Advanced Prostate Cancer : Monitoring Parameters and Safety Profiles. (2) Managing Complications of Chemotherapy., Oncology Pharmacists and Nurses Seminar : Prostate Cancer & Pain Management., 2017-04-22 to 2017-04-22, Johnson&Johnson, (National)
  • Overview of Current Clinical Trials in mHSPC., Southeast Asia Prostate Cancer Core Faculty Meeting (PACER)., 2017-05-06 to 2017-05-06, Johnson&Johnson, (International)
  • Overview of Adjuvant Radiation Therapy in Soft Tissue Sarcoma, Sarcoma Preceptorship, 17 Jul 2017, SINGAPORE., Sarcoma Preceptorship., 2017-07-14 to 2017-07-15, Asian Sarcoma Consortium., (International)
  • Management of Early and Advanced Stage Germ Cell Tumour, JOM 2017, 3 Mar 2017, Johor Bahru MALAYSIA., Johor Oncology Meeting., 2017-08-03 to 2017-08-05, Oncology Department, Hospital Sultan Ismail, Johor Bahru., (National)
  • Renal Cell Carcinoma : Determining Therapeutic Strategy after Disease Progression., PROMISE (PfizeR Oncology Meeting Integrating Science Evidences into clinical practice)., 2017-08-05 to 2017-08-05, Pfizer Oncology., (National)
  • The Science and Treatment Options of CRPC in Malaysia., Meet the Expert Session., 2017-08-19 to 2017-08-19, Bayer, (International)
  • mRCC : Role of Targeted Therapy Beyond First Line., Precision Medicine., 2017-09-04 to 2017-09-06, IKN., (National)
  • LATITUDE Experience, Rethinking Treatment of Metastatic Prostate Cancer, 19 Sep 2017, SINGAPORE., Rethinking Treatment of Metastatic Prostate Cancer : Insights Sharing Session., 2017-09-19 to 2017-09-19, Johnson&Johnson., (International)
  • (1) Advanced Prostate Cancer Highlights from ASCO & ESMO. (2) LATITUDE Insights from LATITUDE Trial Investigator., Advanced Prostate Cancer Workshop., 2017-09-30 to 2017-10-01, Johnson&Johnson, (International)
  • (1) Changing Treatment Landscape of Advanced Prostate Cancer : Current Standard of Care and New Advances. (2) LATITUDE Experience., Brunei Uro-Onco Focus Group Discussion., 2017-11-04 to 2017-11-04, Johnson&Johnson, (International)
  • ESMO Asia Colloquium - Selection Criteria for mCRPC : Bone Targeting Agents, ESMO Asia 2017, 18 Nov 2017, SINGAPORE., ESMO Asia 2017., 2017-11-17 to 2017-11-19, ESMO, SSO, (International)
  • Finding the Magic Bullet - Managing mCNPC in 2017 : A Paradigm Shift? MUC 2017, 26 Nov 2017, Kuching MALAYSIA., 26th Malaysian Urological Conference., 2017-11-25 to 2017-11-25, MUA, (International)
  • 1. Principles of Cancer Therapy, 2. Future of Cancer Therapy., Oncology Colloquium., 2018-02-02 to 2018-02-03, Malaysian Medics International, (International)
  • 1. Optimising Care in mCRPC, 2. Current Standard of Care and New Advances in mCSPC., Optimising Care in Advanced Prostate Cancer, 2018-04-05 to 2018-04-05, Johnson&Johnson, (National)
  • 1. Neoadjuvant and Adjuvant Treatment Soft Tissue Sarcoma, 2. Multidisciplinary Management Sarcoma 3. mHSPC What is the Best Treatment Modality?, Johor Oncology Meeting (JOM), 2018-08-09 to 2018-08-11, Hospital Sultan Ismail JB, (National)
  • Metastatic Castrate Sensitive Prostate Cancer, MEN United V3.0, 2018-08-11 to 2018-08-11, Astellas, (National)
  • Choosing the Most Optimal Treatment Regimen in mHSPC., 1st South East Asia Prostate Cancer Centre of Excellence., 2018-08-17 to 2018-08-18, Johnson&Johnson, Singapore Society of Oncology, Singapore Urological Association, (International)
  • Treatment Sequencing in mCRPC., 1st South East Asia Prostate Cancer Centre of Excellence., 2018-08-17 to 2018-08-18, Johnson&Johnson, Singapore Society of Oncology, Singapore Urological Association, (International)
PRESENTER
  • AGILE study results - UMMC case series, Axitinib : new second line treatment for RCC. Department CME., 2014-03-05 to 2014-03-05, Pfizer Oncology
  • Xeloda in Breast Cancer, Xeloda Preceptorship Programme UMMC March 2014, 2014-03-11 to 2014-03-15, Department of Clinical Oncology, UMMC, (International)
PLEANARY/KEYNOTE SPEAKER
  • Sarcoma : a puzzle, maze of labyrinth?, College of Radiology Annual Meeting, Kuala Lumpur, 2013-06-14 to 2013-06-14, Academy of Medicine, Malaysia Oncological Society, (National)
  • Improving Quality of Life : Treatment That Makes a Difference., Asia Pacific Genitourinary Conference, Bangkok, 2013-07-13 to 2013-07-14, Sanofi Oncology, (International)
  • Prostate Cancer : Current Practise and Future Direction, Philippine Society of Medical Oncology Convention, Manila, 2013-10-16 to 2013-10-17, PSMO Manila, Janssen, (International)
  • Role of Chemotherapy in Castrate Resistant Prostate Cancer, Section of Uro-Oncology Forum : So Many Drugs So Little Time - Prescribing for Uro-Oncology 2014, 2014-06-07 to 2014-06-08, MUA-SUO, (International)
  • Optimal Sequencing of Therapy in Castrate Resistant Prostate Cancer, Section of Uro-Oncology Forum : So Many Drugs So Little Time - Prescribing for Uro-Oncology 2014, 2014-06-07 to 2014-06-08, MUA-SUO, (International)
  • Evolution of Front Line Targeted Therapy in Metastatic Renal Cancer., Section of Uro-Oncology Forum : So Many Drugs So Little Time - Prescribing for Uro-Oncology 2014, 2014-06-07 to 2014-06-08, MUA-SUO, (International)
  • Monitoring and Managing Adverse Events of Targeted Therapy : A Survival Guide for Urologists., Section of Uro-Oncology Forum : So Many Drugs So Little Time - Prescribing for Uro-Oncology 2014, 2014-06-07 to 2014-06-08, MUA-SUO, (International)
  • Prostate Cancer : Follow-Up After Hormonal Therapy and Determining Recurrence., Asia-Pacific Genito-Urinary Oncology Conference, Hong Kong., 2014-07-19 to 2014-07-20, Sanofi Oncology, (International)
  • Past Present and Future of Prostate Cancer Treatment, Prostate Cancer Seminar , 2015-06-13 to 2015-06-13, Johnson&Johnson, (National)
  • Evolving Treatment Landscape in Advanced/Metastatic Urothelial Carcinoma : Where Are We Now and Where We Hope to Go?, MUC 2017, 26 Nov 2017, Kuching MALAYSIA., 26th Malaysian Urological Conference 2017., 2017-11-26 to 2017-11-26, MUA, (International)
ORAL
  • The Status of Radiation Oncology and Management of Locally Advanced Cervical Cancer in Malaysia, IAEA/RCA Regional Training Course on the Optimal Management of Locally Advanced Cervical Cancer, 2007-09-10 to 2007-09-14, IAEA, (International)
  • Lau Kah Liew, Ho Gwo Fuang, Lim Chun Sen, Wong Wai Yan, Marniza Saad, Anita Bustam, Christina Ng. Adjuvant epirubicin, cisplatin and capecitabine (ECX) and chemoradiation with concurrent capecitabine for resected gastric cancer. Malaysian Oncological Society Annual Scientific Meeting, October 2009., ASCOMOS 2009, 2009-10-24 to  , MOS, (International)
  • Marniza Saad, Flora Chong Li Tze, Mastura Md Yusof, Anita Bustam, Ho Gwo Fuang, Daniel Wong Wai Yan, Rozita Abdul Malik, Wan Zamaniah Wan Ishak. Prospective Controlled Study on the role of scalp hypothermia to prevent chemotherapy-induced alopecia in patients with breast cancer receiving anthracycline and taxane-based chemotherapy (SHARE study) : Final Analysis. APCC, Oct 2011., Asia Pacific Cancer Conference 2011, 2011-11-10 to 2011-05-12, Malaysian Oncological Society, (International)
POSTER
  • Cheah SK, Wong DWY, Marniza S, Anita ZB. Pitfalls in radiotherapy - re-irradiation for head and neck cancers. MOS Annual Scientific Meeting, Oct 2008., Malaysian Oncological Society Scientific Meeting 2008., 2008-10-16 to 2008-10-19, Malaysian Oncological Society, (National)
  • Rejab M, Wong DWY, Zamzarinah K, Saad M, Bustam A, Ho GF. Computerized versus conventional planning for craniospinal irradiation of medulloblastoma - a dosimetric study. Malaysian Oncology Society Annual Scientific Meeting , Oct 2008., Malaysian Oncological Society Scientific Meeting 2008, 2008-10-17 to 2008-10-19, MOS, (National)
  • Cheah SK, Wong DWY, Marniza S, Anita ZB. Pitfalls in Oncology : Patient with previous buccal mucosa carcinoma presenting with progressive left hemiparesis. Malaysian Oncological Society Annual Scientific Meeting, October 2008., ASCOMOS 2008, 2008-10-25 to  , MOS, (International)
  • Lau Kah Liew, Marniza Saad, Vivek Ajit Singh. The Outcome of Localised Adult Soft Tissue Sarcoma Treated at University Malaya Medical Centre : Single Institutional Experience, MOS Annual Scientific Meeting, 2010-09-30 to 2010-10-03, MOS, (National)
  • Marniza Saad, Christina Ng Van Tze. Prolonged Survival with Second Line Everolimus in Metastatic Renal Cell Carcinoma after Failure of Tyrosine Kinase Inhibitor. MOS Annual Scientific Meeting, Sep 2010. , MOS Annual Scientific Meeting, 2010-09-30 to 2010-10-03, MOS, (National)
  • Marniza Saad, Flora Chong Li Tze, Mastura Md Yusof, Anita Bustam, Ho Gwo Fuang, Daniel Wong Wai Yan, Rozita Abdul Malik, Wan Zamaniah Wan Ishak. Prospective controlled study on the role of Scalp Hypothermia to prevent chemotherapy-induced Alopecia in patients with breast cancer receiving anthRacycline and taxanE-based chemotherapy (SHARE study). MOS Annual Scientific Meeting, Sep 2010., MOS Annual Scientific Meeting, 2010-09-30 to 2010-10-03, Malaysian Oncological Society, (National)
  • Flora Chong Li Tze, Marniza Saad, Nazarina A..R., Lee M.Y. Fibrosarcoma arising within a dermatofibrosarcoma protuberans with lung metastases : a case report. Malaysian Oncology Society Annual Scientific Meeting, October 2010. , MOS Annual Scientific Meeting, 2010-09-30 to 2010-10-03, MOS, (National)
  • Mohd Izuan Ibrahim, Nani Adilah Suhaimi, Nurain Suhairah Mohmad Kassim, Marniza Saad. Entrance Surface Dose of the Contralateral Breast Using Dynamic and Physical Wedges in the Half-Beam and Open-Field Irradiation Techniques. 2nd UKM-SGH Health Sciences Joint Seminar, April 2011., 2nd UKM-SGH Health Sciences Joint Seminar, 2011-04-09 to  , (National)
  • Marniza Saad, Tang Weng Heng, Marfu'ah Eezamuddeen. Ten year survival in metastatic renal cell carcinoma treated with repeated local treatment and sequential systemic therapy. ACOS, 2012., Asian Clinical Oncology Society Conference, 2012-06-13 to 2012-06-15, ACOS, (International)
  • Sucharit Pongprakyun, Marniza Saad. Dramatic PSA response with third line chemotherapy in metastatic castrate resistant prostate cancer, Annual Scientific Clinical Oncology Meeting, MOS, Sept 2012., ASCOMOS 2012, 2012-09-28 to  , MOS, (International)
  • Mastura Md Yusof, Suhana Yusak, Wan Zamaniah Wan Ishak, Rozita Abdul Malik, Adlinda Alip, Vincent Phua Chee Ee, Marniza Saad.Outcome of Routine Radioiodine Ablation for Differentiated Thyroid Cancer in an Academic Institution. APCC Oct 2013. in Kuala Lumpur, Malaysia, 22nd Asia Pacific Cancer Confefence, 2013-10-31 to 2013-11-02, APCC, (International)
  • Fiona Lian, Marniza Saad, Imran Zainal Abidin, Mun Kein Seong. Meaningful clinical benefit with weekly paclitaxel in primary cardiac angiosarcoma., ASCOMOS 2013, 2013-11-29 to 2013-12-01, MOS, (International)
  • Daniel Gan Eng-Hwee, Teh Yew Ching, Marniza Saad, Tan Gie Hooi, Yip Cheng Har, Nur Aishah Taib. Prevalence and outcomes of primary breast sarcoma and malignant Phyllodes tumour in Asian Women., ASCOMOS 2013, 2013-11-29 to 2013-12-01, MOS, (International)
  • Mastura Md Yusof, Suhana Yusak, Wan Zamaniah Wan Ishak, Rozita Abdul Malik, Adlinda Alip, Vincent Phua Chee Ee, Marniza Saad. Outcome of routine radioiodine ablation for differentiated thyroid cancer in an academic institution in Kuala Lumpur Malaysia., ASCOMOS 2013, 2013-11-29 to 2013-12-01, MOS, (International)
  • Prognostic Factors in Breast Cancer Patients with Brain Metastases., European Society of Medical Oncology., 2015-09-29 to 2015-10-03, ESMO, (International)
  • J Lim, N Bhoo-Pathy, A Alip, M Saad, TA Ong, AHA Razack. The prostate cancer profile in multiethnic Asian men. BJU International 2015, 116, Supplement 4, 1-27., Malaysia Urology Association Annual Scientific Meeting Oct 2015., 2015-10-23 to 2015-10-25, MUA, (International)
  • NK Abd Ghafar, A Alip, TA Ong, M Saad. Efficacy and safety of first line sunitinib in patients with metastatic renal cell cancer: a Malaysian experience from a single tertiary centre. BJU International 2015, 116, Supplement 4, 1-27., 24th Malaysian Urological Association Conference, 2015-11-20 to 2015-11-22, MUA, (International)
  • Treatment outcomes of patients with Metastatic Castrate Resistant Prostate Cancer (MCRPC) on first line docetaxel chemotherapy at University Malaya Medical Centre., Malaysian Urology Conference, 2016-11-24 to 2016-11-26, MUA, (International)
  • The unusual kid on the block:Primary Renal Ewing Sarcoma, Malaysian Urology Conference, 2016-11-24 to 2016-11-26, MUA, (International)
  • Real-World experience with abiraterone in metastatic castrate resistant prostate carcinoma in University Malaya Medical Centre., Malaysian Urology Conference, 2016-11-24 to 2016-11-26, MUA, (International)
  • Treatment Outcome of Metastatic Prostate Cancer Patients Treated at UMMC, ESMO Asia 2016, 2016-12-16 to 2016-12-19, ESMO, SSO, (International)
  • Diagnostic Dilemma : A Case of Metastatic Tubulocystic Carcinoma of Kidney., ESMO Asia 2016, 2016-12-16 to 2016-12-19, ESMO, SSO, (International)
  • Abiraterone in metastatic castrate resistant prostate cancer: outcome and tolerance in real-world setting., 26th Malaysian Urological Conference, 2017-11-23 to 2017-11-25, MUA, (International)
  • Efficacy & Safety of Pazopanib in Advanced Renal Cell Carcinoma : Review in UMMC., ASCOMOS 2017., 2017-12-08 to 2017-12-10, MOS, (International)
  • Efficacy and safety of pazopanib in advanced renal cell carcinoma treated at University Malaya Medical Centre (UMMC)., ASCOMOS 2017, 2017-12-09 to 2017-12-09, Malaysia Oncological Society, (International)
EVENT ORGANISER
  • The Science and Strategy of Cancer Control., 21st Asia Pacific Cancer Conference., 2011-11-10 to 2011-11-12, Malaysia Oncological Society, (International)
  • Musculoskeletal Imaging, COR Annual Scientific Meeting, 2013-06-14 to 2013-06-15, COR, MOS, MSR, (National)
  • Championing Cancer Care in Malaysia, MOS Annual Scientific Meeting, 2013-11-29 to 2013-12-01, MOS, (International)
  • Improving Outcome in the Management of Colorectal Cancer, Colorectal Cancer : An MDT Workshop, 2014-03-29 to 2014-03-29, Department of Clinical Oncology UMMC, Merck Serono, (National)
  • Not applicable., Stereotactic Radiosurgery and Radiotherapy for Cranial Lesions., 2015-05-11 to 2015-05-14, Department of Clinical Oncology, UMMC, (National)
  • S.O.S. Strategise Optimal Solution., Section of Uro-Oncology Forum (SURF)., 2016-04-30 to 2016-04-30, MUA, MOS, (National)
  • Organising Committee : Masterclass in Systemic Anti-Cancer Therapy, Mar 2017, UMMC, KUALA LUMPUR.., MSCT2017., 2017-03-04 to 2017-03-05, Department of Clinical Oncology UMMC., (National)
  • Pushing the Boundaries of Cancer Together., 29th ASCOMOS., 2017-12-08 to 2017-12-10, MOS., (International)
  • 1. Prognostic and Predictive Markers in RCC, 2. Subsequent Lines of Treatment, 3. Side Effects Management, 4. Bone Targeting Agents., Renal Cancer Preceptorship, 2018-05-03 to 2018-05-04, UM, Novartis, (International)
INVITED SEMINAR
  • Panel Discussion on Adverse Event Management, POW WOW RCC Symposium, 2013-04-20 to 2013-04-21, Pfizer, (National)
  • mRCC Optimal Treatment Case Presentation, Leadership & Scientific Exchange Regional Series : Renal Cell Carcinoma, 2016-05-18 to 2016-05-18, Pfizer, (International)
  • Evolving and Emerging Roles of Immunothherapy in Renal and Urothelial Cancers., Immuno-Oncology : New in Cancer Treatment (ICONIC), 2018-03-11 to 2018-03-11, Astra-Zeneca, (National)
  • Optimizing Patient Outcome and Improving Overall Survival in 1st Line mRCC, SUPERDOT (Sharing Sunitinib Experience in Dose Optimisation) (Seminar) (Seminar), 2018-08-09 to 2018-08-09, Pfizer, (National)
  • Updates on Management of Prostate Cancer., Sabah Uro-Onco Focus Group Discussion., 2018-09-06 to 2018-09-06, Johnson&Johnson, (National)
  • Optimizing Patient Outcome and Improving Overall Survival in 1st Line mRCC., SUPERDOT (Sharing Sunitinib Experience in Dose Optimisation), 2018-09-06 to 2018-09-06, Pfizer, (National)
  • 1. Optimizing Patient Outcome and Improving Overall Survival in 1st Line mRCC, 2. Optimizing the Continuum of Care for mRCC Patients., SUPERDOT (Sharing Sunitinib Experience in Dose Optimisation) (Seminar), 2018-09-07 to 2018-09-07, Pfizer, (National)
  • Advanced Prostate Cancer Management Across Asia - Malaysian Experience., Asia Prostate Cancer Experts Meeting, 2018-09-20 to 2018-09-20, Sanofi, (International)
  • 1. Resource-Stratified Practice in Advanced Prostate Cancer Management, 2. Bone-Modulating Agents.in Treatment of Metastatic Prostate Cancer., ESMO Advanced Course on Clinical Question in Prostate Cancer, 2018-09-21 to 2018-09-22, ESMO, SSO, (International)
  • New Approaches in the Treatment of Advanced Prostate Cancer, Hanoi., Treatment of Advanced Prostate Cancer, 2018-10-07 to 2018-10-07, Johnson&Johnson, (International)
CONFERENCE
  • Practical Management of Immune-Mediated Adverse Events - Immunotherapy Pre-Congress Workshop., 52nd Malaysia-Singapore Congress of Medicine, 2018-07-26 to 2018-07-26, Academy of Medicine Malaysia, Malaysia Oncological Society, (International)
  • Shared Decision-Making in Oncology., ECOU 2018 (East Coast Oncology Update), 2018-10-03 to 2018-10-04, Hospital USM, (National)
OTHERS
  • Metastatic CRC : Maintenance treatment or stop-and-go. Which is better?, Colorectal Cancer Workshop, 2014-03-29 to 2014-03-29, Department of Clinical Oncology, Merck, (National)
  • Metastatic Breast Cancer: What can we do today for patients?, Asian Oncology Summit, 2014-04-11 to 2014-04-13, AOS, Elsevier, (International)
  • Preventing SREs in Practice : How early is early in patients with bone metastases., Asian Oncology Summit, 2014-04-11 to 2014-04-13, AOS, Elsevier, (International)
  • A practical approach to optimizing new treatment., Clinical Conversations in mCRPC. , 2014-06-21 to 2014-06-21, Janssen Oncology, (National)
  • Xeloda in Metastatic Breast Cancer, Second Xeloda Preceptorship, 2014-11-11 to 2014-11-14, Department of Clinical Oncology, UMMC & Roche, (International)
  • Breast Cancer Updates., 2015 MOS Annual Scientific Meeting : Evolving Trends in Oncology - From Molecules to Man., 2015-10-17 to 2015-10-18, Malaysia Oncology Society, (International)
  • Not applicable., Preceptorship Programme on Renal Cell Carcinoma - in Collaboration with British Columbia Cancer Centre Canada., 2015-11-27 to 2015-11-28, Pfizer Oncology, BC Cancer Agency Canada, (International)
  • The Current Trend in SRE Prevention in Patients with Bone Metastasis from Prostate Cancer., Section of Uro-Oncology Forum, 2016-04-30 to 2016-04-30, MUA, MOS, (National)
  • Scientific Committee : Masterclass in Systemic Anti-Cancer Therapy, Mar 2017, UMMC, KUALA LUMPUR.., MSCT 2017, 2017-03-04 to 2017-03-05, UMMC, MOS, MOH, UKM, (National)
  • Chairperson : Masterclass in Systemic Anti-Cancer Therapy, Mar 2017, UMMC, KUALA LUMPUR.., MSCT 2017, 2017-03-04 to 2017-03-05, UMMC, MOS, MOH, UKM, (National)
  • Chaiperson : ESCON (Eisai Symposium of Contemporary Oncology) - Renal Cell Carcinoma, 18-19 Mar 2017, TAIWAN., ESCON 2017, 2017-03-18 to 2017-03-19, Eisai, (International)
  • Mentor : Multidisciplinary Case Discussion, Sarcoma Preceptorship 14 Jul 2017, SINGAPORE., Sarcoma Preceptorship, 2017-07-14 to 2017-07-15, Asian Sarcoma Consortium, (International)
  • Chair : Renal Cell Carcinoma Stream - 22-23 Jul 2017, MALAYSIA.., NOVO Summit 2017., 2017-07-22 to 2017-07-23, Novartis, (International)
  • Chairperson : ESMO Asia Colloquium - Selection Criteria for TheTreatment of mCRPC, 17-19 Nov 2017, SINGAPORE., ESMO Asia 2017., 2017-11-17 to 2017-11-19, ESMO, SSO., (International)
  • Judge Oral / Poster : Pushing the Boundaries of Cancer Together, ASCOMOS 2017 8-10 Dec 2017, MALAYSIA., 29th ASCOMOS., 2017-12-08 to 2017-12-10, MOS, (International)
  • Oligometastatic Prostate Cancer., Advanced Prostate Cancer Consensus Conference (APCCC) : Asia-Pacific (APAC) Satellite Symposium., 2018-02-23 to 2018-02-23, ANZUP, (International)

EXPERT LINKAGES
(Linkages Description), (Organisation), (Year of Involvement), (Duration), (Level).


  • Panelist for Advanced Prostate Cancer Consensus Conference (APCCC) - Asia-Pacific (APAC) Satellite Symposium., ANZUP Cancer Trials Group, 2018, 5, (International)
  • Associate Member, UMCRI, 2011, 12, (University)
  • Investigator, Clinical Investigation Centre UMMC, 2006, 72, (University)

EVALUATION ACTIVITIES
(Description), (Evaluation Activity),(Year).


  • Advisor : Phase II Study on the Effect of Oral Gamma-Tocotrienol (G-T3) Supplementation on the Overall Survival and Circulating Tumour Cells (CTC) in Subjects with Castration-Resistant Prostate Cancer (CRPC), Project ,  ( )
  • Expert Panel : Malaysian Consensus on the Advanced Prostate Cancer Consensus Conference (APCCC) 2017 Applicability in Malaysian Setting., Consensus Guideline ,  (2018 - 2018)
  • Reviewer : PSA kinetic as a prognostic in metastatic prostate cancer receiving ADT : systematic review and meta-analysis, Article In Journal ,  (2018 - 2018)
  • Expert Panel : Advanced Prostate Cancer Consensus Conference (APCCC) Asia-Pacific (APAC) Satellite Symposium hosted by ANZUP Cancer Trials Group., Consensus Guideline ,  (2018 - 2018)
  • Evaluator : Combination Effect of Metformin and FEC Chemotherapy on Breast Cancer, MMedSc UM, SSS., Thesis ,  (2014 - 2014)
  • Expert Panel : Depression in Cancer Patient from the Perspective of a Teaching Hospital in Malaysia, MD PhD UM, NCG., Thesis ,  (2014 - 2014)
  • Reviewer : Dramatic and prolonged PSA response with a PSA vaccine., Article In Journal ,  (2012 - 2012)
  • Internal Examiner : Master of Clinical Oncology University Malaya., Examination ,  (2006 - 2018)

CONTRIBUTION TO SOCIETY
(Contribution To Society), (Level), (Start Date), (End Date).


  • Expert Panel at Prostate Cancer Support Group Meeting, 4th July 2019 University Malaya Medical Centre. Prostate Cancer : Newer and Future Treatment., (National), 04/07/2019 until 04/07/2019
  • Guest Speaker for Oncology Colloquium by Malaysian Medics International, 3-4th Feb 2018, UMMC., (National), 03/02/2018 until 04/02/2018
  • Guest Participant at UMMC Candy Girls Year End Party (Breast Cancer Support Group), 30-31 December 2017., (National), 30/12/2017 until 31/12/2017
  • Advisor for Oncology Colloquium by Malaysian Medics International, 3-4th Feb 2018, UMMC., (National), 01/11/2017 until 28/02/2018
  • Panel speaker for Specializing Opportunities Symposium by Malaysian Medics International, 29-30 August 2017, Kuala Lumpur., (National), 29/08/2017 until 30/08/2017
  • Panel speaker for Prostate Cancer Seminar by Prostate Cancer Society Malaysia - Management of Localised and Metastatic Prostate Cancer, 9 August 2017, UMMC., (National), 09/08/2017 until 09/08/2017
  • Panel speaker for Malaysian Enterostomal Therapy Nursing Education Programme (mETNEP) - Role of Chemotherapy and Radiotherapy in Cancerous Wounds and Stoma Care, 20 May 2017, UMMC., (International), 20/05/2017 until 20/05/2017
  • Involved in Candy Girls fitness event Dance into 2017, Dec 2016., (Local), 31/12/2016 until 31/12/2016
  • MC Cooking for Success - workshop for 3rd UMMC Breast Cancer Public Forum Oct 2016., (National), 22/10/2016 until 22/10/2016
  • Organizing Committee for 3rd UMMC Breast Cancer Public Forum Oct 2016., (National), 09/10/2016 until 09/10/2016
  • Spoke on IORT at 3rd UMMC Breast Cancer Public Forum Oct 2016., (National), 09/10/2016 until 09/10/2016
  • Spoke at the Prostate Cancer Support Group Event Oct 2016., (National), 01/10/2016 until 01/10/2016
  • Advisor for Onco-Lead Workshop Aug 2016 - first workshop for trainees & medical officers in oncology., (National), 20/08/2016 until 20/08/2016
  • Sharing Session with Hospis Malaysia Team Aug 2016., (Local), 17/08/2016 until 17/08/2016
  • Gave training on Shared Decision Making at the UMMC-ESG Programme Aug 2016., (National), 13/08/2016 until 13/08/2016
  • Chairperson of Committee for Oncology Dept Family Day Jul 2016., (Department), 30/07/2016 until 30/07/2016
  • Gave a lecture on Oncological Treatment at the Malaysian Hospice Congress Apr 2016., (National), 22/04/2016 until 24/04/2016
  • Article on Prostate Cancer in The Sunday Star 22 November 2015 : Choice in Prostate Cancer - Decoding Your Choice of Care for Prostate Cancer., (National), 22/11/2015 until 22/11/2015
  • Chairperson for the 2nd UMMC Breast Cancer Public Forum Oct 2015., (National), 25/10/2015 until 25/10/2015
  • Featured as an expert panel in 23rd Asia Pacific Cancer Conference Bulletin : Heterogeneity of Prostate Cancer - A Guide to Treatment Choice., (International), 21/08/2015 until 23/08/2015
  • Training for Candy Girls Breast Cancer Survivors - Reaching to Recovery May 2015., (Local), 09/05/2015 until 09/05/2015
  • Medical Advisor to Candy Girls Breast Cancer Survivor Support Group UMMC., (National), 09/05/2015 until 31/05/2016
  • Educational talk to breast cancer survivors in a Pink Ribbon Event : How to Prevent Breast Cancer Recurrence., (National), 20/03/2015 until 20/03/2015
  • Participation in Pink Ribbon event for Breast Cancer Survivors - How to Prevent Recurrence., (National), 19/03/2015 until 21/03/2015
  • Invited panel at the First UMMC Breast Cancer Public Forum 18 Oct 2014 : Why Do I Need Chemotherapy - Factors that Affect Outcome., (National), 18/10/2014 until 18/10/2014
  • Expert panel on national radio station BFM, The Bigger Picture - Kidney cancer and its treatment development. http://www.bfm.my/marniza-saad-kidney-cancer.html , (National), 26/06/2014 until 26/06/2014
  • Annual Scientific Conference of Malaysia Oncology Society (ASCOMOS) Nov 2013 : Scientific Committee., (International), 29/11/2013 until 01/12/2013
  • Annual Scientific Conference of Malaysia Oncology Society (ASCOMOS) Nov 2013 : Chairperson., (International), 29/11/2013 until 01/12/2013
  • Walk for Life to help children with leukaemia., (National), 17/11/2013 until 17/11/2013
  • Musculoskeletal Imaging and Oncology Conference June 2013 : Chairperson for Free Paper Session., (International), 13/06/2013 until 15/06/2013
  • Musculoskeletal Imaging and Oncology Conference June 2013 : Coordinator for Oncology Track., (International), 13/06/2013 until 15/06/2013
  • Featured in Health and Beauty magazine, June 2013 issue : Targeted therapies for Cancer Care., (National), 01/06/2013 until 30/06/2013
  • HELP MAPCU Organ Donation Run 2013 (7km), (National), 26/05/2013 until 26/05/2013
  • Asian Breast Cancer Summit 2013 : Chair for Session 'Beyond Conventional Treatment in Pre-Treated Metastatic Breast Cancer'., (International), 12/04/2013 until 12/04/2013
  • Featured in Health Today magazine feb 2013 issue : Article on the Treatment of Prostate Cancer as part of prostate cancer awareness campaign., (National), 01/02/2013 until 28/02/2013
  • Featured in newspaper : Metro Ahad - Article on prostate cancer : `Kanser ditakuti lelaki'., (National), 06/05/2012 until 06/05/2012
  • Featured in national newspaper : Article on new treatment for prostate cancer., (National), 29/04/2012 until 29/04/2012
  • Chemotherapy Booklet for patients, (Local), 02/01/2012 until 31/12/2012
  • Featured in Oncology Tribune, July 2010 : Article on renal cancer treatment - `MTT improves survival rate in renal cell carcinoma'., (National), 01/07/2010 until 01/07/2010
  • Invited expert panel on national TV station : Hello Malaysia - breast cancer., (National), 27/08/2009 until 27/08/2009
  • Participation in Jacob's Walk of Life to promote healthy lifestyle., (National), 24/06/2007 until 24/06/2007

SUPERVISION


POST GRADUATE STUDENT
(Name of Degree), (Name of Candidates), (Title of Thesis), (Academic Session)

Completed
  • Master Degree, Eznal Izwal Mohd Mahidin, Clinical Supervision, 2016/2017
  • Master Degree, Ang Tick Suan, Clinical Supervision, 2016/2017
  • Master Degree, Leong Siew Mooi, Clinical Supervision, 2015/2016
  • Master Degree, Malwinder Singh Sandhu, Clinical Supervision, 2015/2016
  • Master Degree, Sucharit Pongprakyun, Clinical Supervision, 2015/2016
  • Master Degree, Junie Khoo, Outcome of Metastatic Castrate Resistant Prostate Cancer on Taxane Chemotherapy, 2015/2016
  • Master Degree, Marfuah Nik Eezamuddeen, Clinical Supervision, 2015/2016
  • Master Degree, Junie Khoo Yu Yen, Clinical Supervision, 2015/2016
  • Master Degree, Tang Weng Heng, Clinical Supervision, 2014/2015
  • Master Degree, Tang Weng Heng, Prognostic Factors in Patients with Non-small Cell Lung Carcinoma and Brain Metastases: a Malaysian Perspective, 2014/2015
  • Master Degree, Nahjatul Kursyiah Abd Ghafar, Clinical Supervision, 2014/2015
  • Master Degree, Muthukkumaran A/l Thiagarajan, Clinical Supervision, 2013/2014
  • Master Degree, Noor Zafifah Binti Zakaria, Clinical Supervision, 2013/2014
  • Master Degree, Choong Swee Hsia, Treatment Outcome of Patients with Malignant Spinal Cord Compression in UMMC 2010-2015., 2013/2014
  • Master Degree, Prathepamalar Ap Yehgambaran, Hormonal Therapy in Metastatic Prostate Cancer, 2013/2014
  • Master Degree, Khairiyah Binti Sidek, Evaluation of Patient Satisfaction after First Consultation in Oncology Clinic in UMMC., 2013/2014
  • Master Degree, Nahjatul Kursyiah Bt Abd Ghafar, Clinical efficacy and tolerability of targeted therapy in Malaysian patients with metastatic renal cell cancer, 2013/2014
  • Master Degree, Wong Yoke Fui, Clinical Supervision, 2013/2014
  • Master Degree, Harissa Husainy Hasbullah, Clinical Supervision, 2013/2014
  • Master Degree, Lim Chun Sen, Clinical Supervision, 2013/2014
  • Master Degree, Maryam Hafsah Mohammed Selamat, Awareness of Cognitive Changes & Impact on Functioning at Work : A Qualitative Study in Women with Breast Cancer., 2012/2013
  • Master Degree, Vaishnavi Jeyasingam, Clinical Supervision, 2012/2013
  • Master Degree, Prathepamalar A/p Yehgambaram, Treatment outcome in metastatic prostate cancer patients treated with androgen deprivation therapy in UMMC., 2012/2013
  • Master Degree, Vaishnavi Jeyasingam, Treatment Outcomes of Patients with Inoperable or Metastatic Gastrointestinal Stromal Tumours Treated with Imatinib: A Multicenter Study., 2012/2013
  • Master Degree, Cheah Soon Keat, Clinical Supervision, 2011/2012
  • Master Degree, Fong Chin Heng, Clinical Supervision, 2011/2012
  • Master Degree, Ng Boon Huat, Clinical Supervision, 2011/2012
  • Master Degree, Santhi Nadarajan, Clinical Supervision, 2011/2012
  • Master Degree, Natasha Mohd Hashim, Clinical Supervision, 2011/2012
  • Master Degree, Winnie Ng Nyek Ping, Clinical Supervision, 2011/2012
  • Master Degree, Suhana Yusak, Clinical Supervision, 2011/2012
  • Master Degree, Kua Voon Fong, Clinical Supervision, 2010/2011
  • Master Degree, Arnil George Sirimanne, Clinical Supervision, 2010/2011
  • Master Degree, Tan Chih Kiang, Clinical Supervision, 2010/2011
  • Master Degree, Flora Chong Li Tze, Prospective controlled trial of scalp hypothermia to prevent chemotherapy-induced alpecia in patients with breast cancer receiving anthracycline or taxane-based chemotherapy., 2010/2011
  • Master Degree, Wan Zamaniah Wan Ishak, Clinical Supervision, 2010/2011
  • Master Degree, Hayani Abdul Wahid, Clinical Supervision, 2010/2011
  • Master Degree, Yu Kong Leong, Clinical Supervision, 2010/2011
  • Master Degree, Flora Chong Li Tze, Clinical Supervision, 2010/2011
  • Master Degree, Lee Wei Ching, Clinical Supervision, 2010/2011
  • Master Degree, Hafizah Zaharah Ahmad, Clinical Supervision, 2010/2011
  • Master Degree, Ibtisam Muhammad Nur, Clinical Supervision, 2010/2011
  • Master Degree, Lau Kah Liew, Outcome of Localised Soft Tissue Sarcoma in UMMC., 2009/2010
  • Master Degree, Lau Kah Liew, Clinical Supervision, 2009/2010
  • Master Degree, Ros Suzanna Ahmad Bustamam, Clinical Supervision, 2009/2010
  • Master Degree, Mastura Md Yusof, Clinical Supervision, 2009/2010
  • Master Degree, Rozita Abdul Malik, Clinical Supervision, 2008/2009
  • Master Degree, Rozita Abdul Malik, Pattern of recurrence for non-metastatic invasive breast cancer in UMMC, 2008/2009
  • Master Degree, Chan Wee Han, Clinical Supervision, 2008/2009
  • Master Degree, Vincent Phua Chee Ee, Clinical Supervision, 2007/2008
  • Master Degree, Fabian Lee Wei Yuen, Clinical supervision, 2007/2008
  • Master Degree, Nik Muhd Aslan Abdullah, Clinical Supervision, 2007/2008

Ongoing
  • Master Degree, Noor Nabila Binti Mohamad, Project to be confirmed., 2018/2019
  • Master Degree, Izzati Binti Rosli, Project to be confirmed., 2018/2019
  • Master Degree, Mohd Fahim Bin Abd Rahman, Project to be confirmed., 2018/2019
  • Master Degree, Nurul Iman Binti Fathi, Project to be confirmed., 2017/2018
  • Master Degree, Eng Jie Yi, The use of tiger milk mushroom (TM02) in improving quality of life for end-stage breast cancer patients., 2017/2018
  • Master Degree, Tun Mohd Azlan Bin Mohamed Nor, Prospective Randomised Study of Pharmacokinetics of Low-Dose Abiraterone taken with Low-Fat Malaysian Breakfast Diet Versus Standard Dose Abiraterone Taken At Fasting in Metastatic Castrate Resistant Prostate Cancer and Metastatic Castrate Sensitive Prostate Cancer Patients., 2017/2018
  • Master Degree, Nur Fa'izah Binti Ab Muin, Outcome of Patients with Glioblastoma Multiforme in UMMC., 2017/2018
  • Master Degree, Rizma Binti Mohd Zaid, Project to be confirmed., 2017/2018
  • Master Degree, Vance Koi Yung Chean, An Audit on Treatment Outcome of Bladder Carcinoma in UMMC., 2016/2017
  • Master Degree, Patricia Shamani, Prospective Study of Patiens with Spinal Cord Compression., 2016/2017
  • Master Degree, Syafirin Ab Sani, Denosumab versus Zoledronic Acid in Prevention of ymptomatic Skeletal Events in Patients with Bone Metastases - UMMC Experience 2013-2015., 2016/2017
  • Master Degree, Ngu Ming Ruey, Palliative Oncological Treatment Near End of Life : A UKMMC Experience., 2015/2016
  • Master Degree, Lee Hong Moi, Outcome of Treatment with SRS in Patients with Brain Metastases., 2015/2016
  • Master Degree, Ina Shaliny Duraisamy, Single vs multiple fraction palliative radiotherapy for uncomplicated painful bone metastases treated at University of Malaya Medical Centre: A single institutional Malaysian experience, 2011/2012

TEACHING
(Course Title), (Academic Session), (No of Student), (No of Contact Hours).


POST GRADUATE
  • Master of Clinical Oncology, 2018/2019, 12, 530
  • Master of Clinical Oncology, 2017/2018, 18, 530
  • Master of Clinical Oncology, 2016/2017, 12, 530
  • Master of Clinical Oncology, 2015/2016, 13, 527
  • Master of Clinical Oncology, 2014/2015, 5, 527
  • Masters Of Clinical Oncology , 2013/2014, 7, 520
  • Masters Of Clinical Oncology, 2012/2013, 4, 520
  • Masters Of Clinical Oncology, 2011/2012, 10, 520
  • Master of Clinica Oncology, 2011/2012, 4, 520
  • Masters of Clinical Oncology, 2010/2011, 5, 520
  • Masters of Medical Physics, 2010/2011(1), 4, 2
  • Master of Clinical Oncology, 2009/2010, 6, 520
  • Master of Clinical Oncology, 2008/2009, 6, 520
  • Master of Clinical Oncology, 2007/2008, 6, 530
  • Master of Clinical Oncology, 2006/2007, 6, 530
FIRST DEGREE
  • Bachelor of Medicine, , 150, 24
  • Bachelor of Medicine, 2017/2018, 150, 24
  • Bachelor of Medicine, 2016/2017, 150, 24
  • Bachelor of Medicine UM (UMMP), 2015/2016, 180, 18
  • Bachelor of Medicine UM (UMMP), 2014/2015, 180, 2
  • Bachelor in Medicine : Elective Attachment, 2013/2014, 1, 60
  • Bachelor of Medicine - Elective, 2013/2014, 1, 160
  • Degree in Nursing, 2007/2008, 40, 1
  • Degree in Nursing, 2006/2007, 36, 1
DIPLOMA (IF APPLICABLE)
  • Advanced Diploma in Oncology Nursing, 2008/2009, 20, 4
  • Advanced Diploma in Oncology Nursing, 2006/2007, 15, 4